The impact of Indigenous American-like ancestry on risk of acute lymphoblastic leukemia in Hispanic/Latino children

Jalen Langie[1,2], Tsz Fung Chan[1,2], Wenjian Yang[3], Alice Y. Kang[4], Libby Morimoto[4], Daniel O. Stram[5], Nicholas Mancuso[1,2], Xiaomei Ma[6], Catherine Metayer[4], Philip J. Lupo[7,8], Karen R. Rabin[7,8], Michael E. Scheurer[7,8], Joseph L. Wiemels[1,2], Jun J. Yang[3], Adam J. de Smith[1,2,10], Charleston W.K. Chiang[1,2,9,10]

[1] Center for Genetic Epidemiology, Department of Population and Public Health Sciences, University of Southern California Keck School of Medicine, Los Angeles, CA, USA.

[2] USC Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, CA, USA.

[3] Department of Pharmacy and Pharmaceutical Sciences, St. Jude Children's Research Hospital, Memphis, Tennessee, USA.

[4] School of Public Health, University of California Berkeley, Berkeley, CA, USA.

[5] Department of Population and Public Health Sciences, University of Southern California Keck School of Medicine, Los Angeles, CA, USA.

[6] Department of Chronic Disease Epidemiology, Yale School of Public Health, New Haven, CT, USA.

[7] Division of Hematology-Oncology, Department of Pediatrics, Baylor College of Medicine, Houston, TX, USA.

[8] Texas Children's Cancer and Hematology Centers, Texas Children's Hospital, Houston, TX, USA.

[9] Department of Quantitative and Computational Biology, University of Southern California, Los Angeles, CA, USA.

[10] Co-senior authors

Abstract:

Acute lymphoblastic leukemia (ALL) is the most common childhood cancer, with Hispanic/Latino children having a higher incidence of ALL than other racial/ethnic groups. Genetic variants, particularly ones found enriched in Indigenous American (IA)-like ancestry and inherited by Hispanics/Latinos, may contribute to this disparity. In this study, we characterized the impact of IA-like ancestry on overall ALL risk and the frequency and effect size of known risk alleles in a large cohort of self-reported Hispanic/Latino individuals. We also performed genome-wide admixture mapping analysis to identify potentially novel ALL risk loci. We found that global IA ancestry was positively associated with ALL risk, but the association was not significant after adjusting for socio-economic indicators. In a series of local ancestry analyses, we uncovered that at known ALL risk loci, increasing copies of the IA-like haplotype were positively and significantly associated with ALL case-control status. Further, the IA-like haplotype had ~1.33 times the odds of harboring the risk allele compared to non-IA-like haplotypes. We found no evidence of interaction between genotype and ancestry (local or global) in relation to ALL risk. Admixture mapping identified association signals on chromosomes 2 (2q21.2), 7 (7p12.2), 10 (10q21.2), and 15 (15q22.31); however, only the variants at 7p12.2 and 10q21.2 replicated in additional cohorts. Taken together, our results suggest that increased risk of ALL in Hispanic/Latino children may be conferred by higher frequency of risk alleles within IA-like ancestry, which can be leveraged as targets of new precision health strategies and therapeutics.

Introduction:

Acute lymphoblastic leukemia (ALL) is the most common childhood cancer and accounts for

25% of malignancies before the age of 20[1]. The long-term survival rate of the disease in

children is high, occurring upwards of 85-90% [2]; however, this survival decreases to 30-40% in

individuals over the age of 35, to approximately 40% after relapse[3–5], and in 2024 an estimated

1,330 adults and children died of ALL[6–9]. Despite decades of investigation into ALL risk, the

etiology of the disease is not well understood and disparities in risk persist. Children of

Hispanic/Latino ethnicity have 1.4 and 2 times the risk of developing ALL compared to their

Non-Latino White and Black counterparts, respectively[10] . This disparity in risk widens in margin

for Hispanic/Latino adults[10] and is specific to the B-cell immunophenotype, which comprises

approximately 85% of cases[11] . While environmental factors are involved in this increased risk,

genetic factors likely contribute at least in part to this disparity[12,13]

76
The genetic basis of ALL can be evaluated using migration studies, ecological data, time trends,

heritability, and admixture and genetic studies[14] . Previous migration studies have indicated that

foreign- and US-born Hispanics/Latinos have comparable rates of B-cell ALL to each other, and

both have higher (~2.13 times) incidence rates compared to Non-Latino Whites[15,16]. The stark

difference in incidence between Hispanics/Latinos and Non-Latino Whites, as well as the

similarities in rates between US-born and foreign-born Hispanics/Latinos, may indicate a

substantial genetic component to the disease, rather than a primarily environmental etiology.

Further, ecological data has indicated that, in 2017, the countries with highest age standardized

incidence rates of ALL were in Latin America (*i.e.* Honduras and Mexico), while countries with the

lowest incidence rates were in Africa, with European countries exhibiting intermediate

incidence[17,18] . Most directly, previous genome-wide association studies (GWAS) have estimated

the heritability of ALL to be approximately 18-21% in both Hispanic/Latino and Non-Latino White

populations, and approximately 24% of familial relative risk has been attributed to known ALL risk

variants[19–21] . Consistent with these estimates, GWAS have identified a number of loci associated

with ALL susceptibility, including risk alleles located near genes such as *IKZF1*, *ARID5B*, *GATA3*,

and *ERG* that appear to be enriched in frequency or show stronger effects in Hispanic/Latino

populations[13,22–24].

Notable amongst populations with differing incidence rates of ALL is the presence or dominance

of a particular ancestry component. Hispanics/Latinos are an admixed population - drawing

ancestral components from the American, European, and African continents[25,26] . Previous

literature has alluded to associations between Indigenous American (IA)-like ancestry and ALL,

suggesting that every 20% increase in IA-like ancestry was associated with a 20% increase in

odds of developing B-cell ALL[27]. Because Hispanics/Latinos inherited a significant proportion of

their genetic ancestries from Indigenous Americans (though there is geographical heterogeneity

across the Americas), these associations with respect to global IA-like ancestries may be

consistent with the migration and ecological findings above. However, associations with global

ancestry can be confounded by non-genetic factors such as socio-economic status[28], for which

the aforementioned analyses did not adjust. Relevant to the discussion of the role of the IA-like

haplotype in ALL risk is local ancestry, or ancestry in a particular location of the genome[29]. Local

ancestry analyses are less susceptible to confounding by environmental factors, and have yielded

promising results in determining the association between IA-like ancestry and leukemia risk. For

example, a study of the *ERG* locus found that Hispanics/Latinos who had 1 or more copies of the

IA-like haplotype at the locus had 1.15-1.30 times the odds of developing ALL compared to

Hispanics/Latinos with 0 copies of the haplotype[30] . Together, these data suggest that in addition

to the environmental basis of disease, higher frequencies of risk alleles present in the IA-like

ancestry component inherited by many Hispanics/Latinos may be contributing to disproportionate

risk of ALL.

Given the important role of genetic factors and genetic ancestry in ALL risk, we undertook a

systematic admixture analysis in the largest ALL cohort of self-reported Hispanic/Latino children

to date. We investigated both inferred global ancestry across the genome and local ancestry at

known ALL loci for associations with risk, and further conducted admixture mapping to detect

novel risk loci that may exhibit frequency differences between ancestries and, consequently,

contribute to the disparities between populations. We note that given our goal to further

understand the disparity in ALL risk epidemiologically observed among Hispanic/Latino children,

we focused on inferring the genetic ancestries and characterizing their impact on ALL from self-

reported Hispanic/Latino individuals. We defined genetic ancestries at the continental (e.g. Africa,

Europe, and Americas) level, representing patterns of genetic similarities across geographical

space over the last ~10-50k years due to human migrations and isolation-by-distance. These

relatively distinct components of ancestries, though arbitrarily defined, are only recently reunited

in admixed populations, such as in Hispanics/Latinos. These components are inferred and defined

relative to reference populations available to us, and are leveraged to uncover associations with

traits in this research setting, but are invariably a simplified representation of the complex nature

of genetic ancestries. We thus append the suffix "-like" to refer to these ancestries to remind the

reader of this simplification and uncertainty[31].

Methods:

Study Subjects and Quality Control

We use the term "Hispanics/Latinos" as a population descriptor of our study subjects to align with

both the self-reported race/ethnicity categories and the definitions of the USA Office and

Management Budget[32] , while acknowledging that we focus on individuals of Latin American

origin. Our analysis utilized the following cohorts of self-reported Hispanics/Latinos: the California

Cancer Linkage Project (CCRLP), the Kaiser Resource for Genetic Epidemiology Research on

Aging Cohort (Kaiser-GERA), the California Childhood Leukemia Study (CCLS), Children's

Oncology Group (COG), Multi-Ethnic Study of Atherosclerosis (MESA), the Adolescent and

Childhood Cancer Epidemiology and Susceptibility Service for Texas and Reducing Ethnic

Disparities in Acute Leukemia (ACCESS/REDIAL), and the Hispanic Community Health

Study/Study of Latinos (HCHS/SOL). All relevant information on sample size, arrays, study

design, and references/dbGaP accession numbers can be found in **Table 1**. Following the

practice in previous studies[13,19,33], cases from CCRLP were augmented with external controls

from Kaiser-GERA due to being genotyped on a similar array. Cases from COG were paired with

external controls from MESA and ACCESS/REDIAL cases were paired with external controls from

HCHS/SOL. HCHS/SOL was a multi-center study, with study participants being ascertained from

Bronx, New York; Chicago, Illinois; Miami, Florida; and San Diego, California. The SOL San Diego

center was chosen as controls for ACCESS/REDIAL due to similarity in the first 2 principal

components and estimated ancestry distributions (**Supplementary Figures 1-2**).

156
157

Study	In-Text Name/ Acronym	Study Design	N	Genotype Array	Reference/ Accession Number	Usage
California Cancer Linkage Project	CCRLP	Population Based case-control study	4033	Affymetrix Axiom World Array	Wiemels et al., 2018[33]	Global and local ancestry analyses; Discovery Admixture Mapping Cohort (combined with Kaiser-GERA)
Kaiser Resource for Genetic Epidemiology Research on Aging Cohort	Kaiser-GERA	Cohort study (controls only)	6417	Affymetrix Axiom World Array	phs000788.v1.p2	Discovery Admixture Mapping Cohort (combined with CCRLP)
California Childhood Leukemia Study	CCLS	Population Based case-control study (cases and controls)	1120	Illumina OmniExpress v.1	Ma et al., 2004[34]	Global and local ancestry analysis; Replication cohort
Children's Oncology Group (AALL0232, COG9904/9905)	COG	Clinical Trial (cases only)	836	Genome-Wide Human SNP Array 6.0	phs001350.v1.p1	Replication Cohort (combined with MESA)
Multi-Ethnic Study of Atherosclerosis	MESA	Cohort Study (controls only)	1118	Genome-Wide Human SNP Array 6.0	phs000209.v13.p3	Replication Cohort (combined with COG)
Adolescent and Childhood Cancer Epidemiology and Susceptibility Service for Texas and Reducing Ethnic Disparities in Acute Leukemia	ACCESS/ REDIAL	Hospital Cases (cases only)	510	Illumina Global Screening Array	Harris et al., 2023[35]	Replication Cohort (combined with HCHS/SOL)
Hispanic Community Health Study/Study of Latinos	HCHS/SOL	Cohort Study (controls only)	2285	Illumina Omni2.5M array	phs000810.v2.p2.c2; phs000810.v2.p2.c1	Replication cohort (combined with cases from Texas)

Table 1: All cohorts included in the analysis. *Information includes title, design, sample size, genotype array, dbGaP accession*

number or reference, and how each study was used in our analysis.

All analyses were limited to autosomes. Within each study, SNPs and individuals were removed

based on the following pre-defined quality control thresholds: SNP call rate < 0.98, MAF < 0.01,

$p_{HWE} < 1 \times 10^{-5}$, high relatedness ($\hat{\pi} > 0.2$), Genome Heterozygosity Rate > 6 standard

deviations from the mean, or sample call rate < 0.95. Palindromic SNPs were also excluded as

they could impact imputation accuracy due to unidentified strand flip or inversion between genome

build[36] . The number of individuals and SNPs remaining can be found in **Supplementary Table**

1. Local ancestry was inferred using RFMIX[37]. Reference haplotypes were obtained from the

genome aggregation database (gnomAD)[38] version 3, including 708 African, 671 Non-Finnish

European, and 94 Indigenous American individuals previously chosen for ancestry inference in

Hispanics/Latinos[39] . After restricting to the intersection of SNPs across each paired dataset, each

dataset was imputed separately using the TopMed Imputation Server[40] (Kowalski et al., 2019).

We observed systemic differences in imputation quality as measured by the imputation R^2

between cases and external controls, presumably due to batch effects in data generation or subtle

differences in ancestry compositions between cohorts and differential imputation accuracies

across populations[41]. Consequently, for all comparisons of cases to controls, we imposed filters

such that only SNPs with an imputation $R^2 > 0.30$ in both cases and controls and a R^2 difference

< 0.15 between cases and controls were included in the analysis.

<u>Harmonizing self-reported ethnicity and genetically inferred ancestry labels in CCRLP/Kaiser-</u>

<u>GERA</u>

To explore our data and investigate the concordance of self-reported race/ethnicity information

and genetically inferred ancestry, we plotted the first 20 Principal Components of multi-ethnic

CCRLP-Kaiser/GERA study participants (10450 Hispanic/Latino, 2191 Non- Latino African, 5335

Non-Latino East Asian, 58503 Non-Latino European) and implemented a software, Harmonizing

Ancestry and Race Ethnicity[42] (HARE). HARE is a two-step algorithm that identifies individuals

who may be discordant between self-identified race/ethnicity (SIRE) and genetically inferred

ancestry (GIA), given the mapping of the two learned from the rest of the dataset. The first step

is a training phase in which genetically inferred ancestry based on principal components are used

to predict available self-reported race/ethnicity in a support vector machine. The second step is

HARE strata assignment, in which the highest probability of being assigned to a stratum is

contrasted with the probability that the individual belongs to their self-reported stratum using

preset thresholds. We ran HARE with the default parameters and thresholds[42] . The multi-class

support vector machine, with a radial kernel, was trained on the first 30 principal components

calculated using PLINK[43] (v2.0) of genotype data from individuals of across all race/ethnicity

groups from CCRLP/Kaiser-GERA to predict self-reported race/ethnicity. Then, the HARE

algorithm compared the predicted probability of membership in the most likely strata based on

genetics to the predicted probability of membership of an individual's SIRE. If the ratio of the

probabilities exceeds a pre-defined threshold, an individual with existing SIRE could be assigned

as missing (*i.e.* removed from analysis), while an individual without SIRE would be assigned into

the top predicted strata. We first evaluated if the HARE algorithm would assign any of the study

participants as missing due to discordance between SIRE and GIA. We also assessed the rate of

discordance between SIRE and GIA by performing 10-fold cross validation in which we randomly

masked the SIRE information of 10% of study participants for each race/ethnicity group in each

trial. Percent discordance was defined as the number of individuals with self-identified race-

ethnicity data classified as missing or as a stratum not corresponding to the true self-reported

race/ethnicity label.

Global Ancestry Analyses

Global ancestry for each study participant was calculated by averaging local ancestry across the

genome. We performed logistic regression of ALL case-control status on global IA-like ancestry

in CCRLP and CCLS, studies in which indicators of socio-economic status (SES) variables were

available. Covariates included African-like ancestry, sex, and SES indicators (highest education

obtained by a parent and annual household income). Income was categorized in 6 strata, in

accordance with its treatment in CCLS[44] : <$15,000, $15,000-$29,999, $30,000-$44,999,

$45,000-$59,999, $60,000-$74,999, and >$75,000. In CCLS, highest educational attainment of

either parent was divided into 4 categories: Less than elementary school, high school, some

college, and a bachelor's degree or higher. In CCRLP, the strata were less than 9th grade, 9th-12th

grade, and some college or more. Both SES indicators were treated as ordinal categorical

variables, in which the lowest category was used as a reference. Linearity assumptions were

assessed using residual and QQ plots. Analysis was carried out using R v.4.3.1[45].

Enrichment of risk allele on IA-like ancestry haplotypes

We performed a series of local ancestry analyses at known ALL loci. A list of all currently known

ALL loci was obtained from[12] . We restricted analyses to SNPs that were independent at the local

ancestry level (N=20), which was determined via PLINK's clumping algorithm[46]. SNPs were

clumped if the local ancestry calls covering the SNPs were 90% correlated within 10 Mb of each

other. We excluded the T-cell ALL-specific association locus at USP7[47] given that the increased

risk of ALL in Hispanics/Latinos is limited to B-cell ALL. Across known ALL loci[12], we cross-

tabulated local genetic ancestry (number of copies of the IA-like, African-like, or European-like

haplotypes) and risk allele dosage. Then, we identified randomly in-sample 20 frequency-matched

alleles from across the genome and cross tabulated the occurrence of this pseudo risk allele with

ancestry dosage to establish a null distribution. Co-occurrence of the risk allele with a particular

ancestry haplotype would imply association. Differences between the null and known loci

distribution were evaluated via a Chi-Squared Goodness of Fit test. We also performed a logistic

regression of ALL case-control status on IA-like ancestry dosage at each locus, including as

covariates global African-like and European-like ancestry, and sex. To test for presence of

heterogeneous effect sizes across ancestries, we performed logistic regression of ALL case-

control status on risk allele genotype, IA-like ancestry dosage, sex, the first 20 principal

components, and an interaction term of local ancestry and risk allele dosage. Analyses were

carried out either using PLINK v2.0[43] or R v.4.3.1[45].

<u>Admixture mapping, regional association testing, and replication</u>

We performed a genome-wide scan for loci in which IA-like ancestry was associated with ALL

risk. We regressed ALL case-control status on the local IA ancestry dosage, global African-like

and European-like ancestry, sex, and the first 20 principal components. We performed this

analysis in CCRLP/Kaiser as our discovery dataset. The significance threshold for genome-wide

admixture mapping was 5.7×10^{-5}, as suggested in literature previously for Hispanic/Latino

populations[48,49].

After identifying potential signal through admixture mapping in CCRLP/Kaiser, we then fine-

mapped the admixture peak through single-variant association testing in the same dataset. The

admixture peak region[50] was defined as a range of positions that contains all SNPs with a -

log10(P) between -log10(P_{am}) and -log10(P_{am}) $- 1$, with P_{am} representing the p-value associated

with the lead SNP from admixture mapping. Genotypes of all imputed SNPs within this region

passing QC filtering were tested via logistic regression, with sex and the first 20 principal

components as covariates. To compute the significance threshold for each region, we permuted

case-control labels 1000 times and recorded the minimum p-value per permutation. The fifth

percentile of all permutation trials was recorded as the significance threshold per region. The most

significant variant from each peak region was assumed to be the putative causal variant, which

we then verified through a conditional analysis by including it as a covariate in the admixture

mapping regression model to determine if the admixture signal would be attenuated. We

attempted to replicate the signals at the lead variants from regional association testing and

conditional analysis in additional Hispanic/Latino cohorts: CCLS, COG/MESA, and SOL-

SD/REDIAL. The replication cohorts were meta-analyzed together by inverse variance weighting

in the software *METAL*[51].

<u>IRB Statement:</u>

This study was approved by the institutional review boards of the California Health and Human

Services Agency, the University of Southern California, Children's Oncology Group, Baylor

College of Medicine, Yale University, and University of California, Berkeley. All study participants

were de-identified and newborn bloodspots from the CCRLP were obtained via a consent waiver

from Committee for the Protection of Human Subjects of the State of California.

<u>Results:</u>

GWAS are often conducted stratified by race/ethnicity or ancestry in order to identify population-

specific associations or to control for confounding due to population stratification[52] (Peterson et

al., 2019). The stratifying demographic variable can appear in the form of self-reported race and

ethnicity, such as information from electronic health records, or inferred ancestry from genetic

data, such as through principal component analysis or global ancestry estimates. Usage of one

over the other is dependent on the goals of the study. Our study investigates genetic ancestry as

it relates to ALL and is largely based on the Hispanic/Latino subset (N = 4033) of the CCRLP

study, a population-based case-control study established in California. Moreover, we leverage

previous study designs, including the CCRLP and additional Hispanic/Latino cohorts, to map

potentially novel loci associated with ALL via admixture mapping. CCRLP, supplemented with

external controls from the Kaiser-GERA cohort, is the largest cohort we have access to and serves

as the discovery cohort (**Table 1**). Consequently, we first sought to characterize the distribution

of genetic ancestries in CCRLP, and to re-examine the impact, if any, of using self-reported

Hispanic/Latino ethnicity for our analyses.

Harmonizing self-reported ethnicity with genetic ancestry in CCRLP/Kaiser-GERA

The CCRLP/Kaiser-GERA cohort[19,33] (Wiemels et al., 2018; Jeon et al., 2022) is comprised of

four self-reported strata of ethnicities: Non-Latino Black (AFR; N = 2,191), Non-Latino East Asian

(EAS; N = 5,335), Hispanic/Latino (LAT; N = 10,450), and Non-Latino White (NLW; N = 58,503).

We examined the first 20 axes of the principal components analysis applied to the genetic data

(**Figure 1, Supplementary Figure 3**). Consistent with previous multi-ethnic studies (Wojcik et al.,

2019), on the first two axes, individuals fall into a cline according to their genetic ancestry, with

the three main components being driven by ancestries found most prevalently among self-

reported non-Latino African individuals, non-Latino European individuals, and non-Latino East

Asian individuals, representing the three vertices of the plot (**Figure 1**). In these two axes, self-

reported Hispanic/Latino individuals are scattered between all three ancestry components. While

they may appear to be genetically similar to those self-reported as East Asians in the cohort, the

third principal component axis shows the divergence between Hispanics/Latinos and East Asians,

reflecting the divergence between East Asian-like and Indigenous American (IA)-like ancestries

(**Supplementary Figure 3**. The relatively higher similarity between these two ancestries due to

their more recently shared history[53] likely contributed to the pattern on the first two PCs.

Figure 1: Principal component Analysis (PCA) plot of multi-ethnic study participants of CCRLP-Kaiser. Individuals in red, yellow, green, and blue are self-

reported Non-Latino Black, Hispanic/Latino, Non-Latino White, and Non-Latino East Asian individuals, respectively. Each individual from CCRLP or Kaiser/GERA

is labeled with C or K, respectively.

We first investigated if the self-reported strata are consistent with the pattern from genetic data.

We applied a machine-learning based algorithm, Harmonization Ancestry and Race/Ethnicity

(HARE), which leverages the genetic similarities between individuals as represented in multi-

dimensional principal components space to identify discordances between self-labelled strata

with inferred genetic similarities or to impute missing self-labels[42]. Since self-reported ethnicities

are available for all individuals in CCRLP/Kaiser-GERA, we first evaluated the proportion of

individuals where the HARE algorithm identified strong discordance between the self-report and

the genetically inferred ancestry based on the top 30 PCs; these discordant individuals could be

considered for exclusion in downstream analysis. Overall, we found very low proportions of

samples with clear discordant labels (percent discordance = 0.47% overall, and 0.68%, 3.37%,

0.18%, and 0.54% for AFR, EAS, EUR, and LAT study participants, respectively (**Supplementary**

Table 2).

We also evaluated the discordance between self-reported strata and genetically inferred

ancestries in the HARE algorithm under its imputation mode by randomly dividing the entire

dataset into ten equal subsets and masking one subset at a time. In this mode, the recall

percentages were 82.6%, 86.9%, 77.5%, and 61.5% for AFR, EAS, NLW, and LAT, respectively.

In particular, among the ~38.5% of LAT individuals where the self-reported label was not recalled,

63.5% were considered missing because the algorithm had no clear call, while the remaining

were categorized into the other labels (0.80%, 0.42%, and 35.3% to AFR, EAS, and NLW,

respectively) and an overall distribution of estimated ancestries biased towards European-like

ancestry (**Supplementary Table 3; Supplementary Figure 4**). Trusting that any mis-labels (e.g.

transcription errors) of self-reports must be rare, and the extremely low discordance when all self-

reported labels are used (0.54% for LAT), we elected to proceed with our analysis using all self-

reported LAT individuals. Individual samples would only be removed from analysis due to

technical concerns identified during the quality control process, rather than excluded as, for

instance, an ancestry outlier based on a rather vague and undefinable criteria. Nevertheless, the

lower recall of LAT individuals when self-reported labels are unavailable highlights the

heterogeneity of LAT that exist. We thus also conducted the admixture mapping analysis using

the subset of ~61.5% LAT individuals based on genetically inferred ancestry to validate our

results; we found qualitatively concordant results (see below).

The association between Indigenous American-like ancestries, ALL risk, and SES indicators

To quantify the effects of IA-like ancestry on ALL risk, we tested the association between ALL

case-control status and global IA-like ancestry, while adjusting for African-like ancestry, sex, as

well as covariates that are proxies for socioeconomic status (SES), such as highest parental

education, and annual household income. We performed these assessments for all self-reported

LAT individuals in both CCRLP (excluding Kaiser-GERA controls; N = 4033) and CCLS (N = 605),

as both of these cohorts contained internal controls and are less likely to be confounded due to

their study design. In CCLS, IA-like ancestry was significantly associated with ALL risk, prior to

including SES indicators in the model, as previously reported (Walsh et al., 2013). In the base

model adjusting for sex and African-like ancestry, a 20% increase in IA-like ancestry was

associated with a 23% (OR: 1.23, 95% CI: 1.07-1.42; P = 0.003) increase in odds of developing

ALL. However, this association appears confounded, as inclusion of SES covariates strongly

attenuated the strength of association (OR: 1.12; 95% CI: 0.96-1.31) and case/control status is

no longer significantly associated with IA-like ancestry ($P = 0.$159*;* **Supplementary Table 4**). In

CCRLP, IA-like ancestry was not significantly associated with ALL risk in the base model adjusting

for only African-like ancestry and sex, and did not qualitatively change when SES covariates were

included (**Supplementary Table 4**).

To further support that SES indicators (education level and income) were confounders in the

association between ancestry and disease risk, we first examined associations between SES

indicators and disease risk. In CCLS, where we observed an attenuation of association after

adjusting for SES, higher income was associated with lower risk of disease, with those belonging

to higher income strata having with 0.27 to 0.76 times the odds of developing ALL (p-value range:

2.13×10^{-5} – 0.153; Supplementary **Table 5**). Parental education was not associated with case-

control status, though showing the expected trend that higher education is associated with lower

risk of disease (**Supplementary Tables 6**). In CCRLP, neither income nor parental education

were significantly associated with ALL case-control status (**Supplementary Tables 5-6**).

Next, we evaluated the relationship between ancestry and SES variables. Ancestry are often

correlated with SES indicators because they are correlates of self-reported race-ethnicity[28,54].

Self-reported race/ethnicity can act as a proxy for various socio-cultural factors, including access

to opportunities, healthcare, or education, which suggests that associations between ancestry

and variables such as income or educational attainment reflect environmental effects rather than

those arising from genetics[42,55,56]. Consequently, in previous studies, adjustment for SES

variables often attenuates the association between global ancestry and disease[28,57,58]. Consistent

with the literature, in both CCLS and CCRLP, we observed a positive correlation between

European-like ancestry and high socio-economic status (**Supplementary Tables 7-8**). Taken

together, because SES measures can correlate with both ancestry and disease risk, it likely

confounded the previously observed association[27] between IA-like ancestry and ALL risk in CCLS.

Known ALL risk loci are enriched among Indigenous American-like ancestries

We further examined the pattern of local IA-like ancestry at known ALL risk loci (**Supplementary**

Table 9). First, we tabulated the proportion of times the risk allele at known ALL loci is associated

with the African-like, IA-like, or European-like ancestry haplotypes, and compared these to the

proportions found across 1000 sets of SNPs randomly selected across the genome and matched

by the risk allele frequencies. Across a total of 20 SNPs from 20 loci, the risk alleles were found

on the African-like, IA-like, and European-like ancestry haplotypes 5.76%, 45.35%, and 48.88%

of the time, respectively, in CCRLP. This significantly deviates from the genome-wide expectation

(4.83%, 43.33%, and 51.85% for African-like, IA-like, and European-like ancestry haplotypes; p-

value = 1.042×10^{-36} by a chi-square goodness-of-fit test), with IA-like haplotypes showing a

significant enrichment in association with the risk alleles. We also replicated this observation in

CCLS, with IA-like haplotypes enriched with ALL risk alleles (p-value = 1.629×10^{-9}). Consistent

with this finding, the IA-like haplotypes have 1.32-1.33 (95% CI: 1.29 - 1.36 in CCRLP, 1.26-1.41

in CCLS) times the odds of carrying the risk allele compared to Non-IA-like haplotypes (p =

5.61×10^{-88} and 2.61×10^{-23} in CCRLP and CCLS, respectively; **Supplementary Table 10**).

If risk alleles for ALL are found disproportionately on IA-like haplotypes at known loci, we would

expect that IA-like ancestries show an enrichment of association in admixture mapping studies.

As expected, when we regressed ALL case-control status on the number of copies of IA-like

ancestry segments locally at each known ALL locus, while adjusting for sex and global African

and European ancestry proportions, we found a positive association with ALL at 14 out of 20

known B-cell ALL loci. At all loci in which IA-like ancestry was significantly associated with ALL at

the 0.05 level, IA ancestry was positively associated with risk (Binomial test, p = 0.008 **Table 2**).

Taken together, our results suggest that IA-like haplotypes are enriched for association with

increased ALL risk at known loci.

427
428
429
430

Gene	Chr	Location	OR	L95	U95	P-value[a]
BCL11A	2	2p16.1	0.94	0.86	1.02	0.138
RPL6P5	2	2q22.3	1.01	0.93	1.10	0.751
C5orf56	5	5q31.1	1.07	0.98	1.17	0.113
BAK1	6	6p21.31	0.946	0.87	1.03	0.208
MYB/HBS1L	6	6q23	0.99	0.91	1.07	0.749
IKZF1	**7**	**7p12.2**	**1.32**	**1.21**	**1.43**	**2.990×10^{-10}**
CCDC26	8	8q24.21	0.93	0.85	1.01	0.084
CDKN2A/2b	9	9p21.3	0.93	0.86	1.02	0.115
TLE1	9	9q21.31	1.04	0.96	1.13	0.358
GATA3	**10**	**10p14**	**1.14**	**1.04**	**1.24**	**0.003**
BMI1/PIP4K2A	**10**	**10p12.2/10p12.31**	**1.16**	**1.07**	**1.27**	**5.422×10^{-4}**
ARID5B	**10**	**10q21.2**	**1.29**	**1.19**	**1.41**	**4.924×10^{-9}**
JMJD1C	**10**	**10q21.3**	**1.27**	**1.16**	**1.38**	**5.383×10^{-8}**
TET1	**10**	**10q21.3**	**1.15**	**1.06**	**1.25**	**0.001**
LHPP	10	10q26.13	0.97	0.89	1.06	0.508
ELK3	**12**	**12q23.1**	**1.10**	**1.01**	**1.19**	**0.038**
CEBPE	**14**	**14q11.2**	**1.10**	**1.01**	**1.20**	**0.022**
IKZF3	17	17q21.1	1.03	0.95	1.11	0.515
IGF2BP1	17	17q21.32	1.02	0.93	1.11	0.728
ERG	21	21q22.2	1.02	0.93	1.11	0.711

431
432 ***Table 2: Indigenous American-like ancestry is positively associated with risk at known ALL***

433 ***loci.*** *ALL case-control status was regressed on local Indigenous ancestry dosage, African-like*

434 *and European-like global ancestries, and sex[a]. Loci that reach nominal significance (P < 0.05) are*

435 *in **bold**)*

In addition to ALL risk alleles being found more prevalently on IA-like haplotypes, risk alleles may

also exert larger (or smaller) effects on ALL when they are found on the IA-like background. We

tested for effect size heterogeneity by including a SNPxAncestry interaction term in the standard

association testing model. After Bonferroni correction, no significant interactions between

genotype and local IA-like ancestry were observed in either CCRLP or CCLS, or when the two

cohorts were combined (**Supplementary Table 11**). We additionally found no evidence of

interaction between global IA ancestry and genotype (**Supplementary Table 12**). Therefore, we

found no evidence that ALL risk alleles may exert larger effects on an IA haplotype than on other

haplotypic backgrounds.

Admixture mapping proposes putative novel ALL loci associated with Indigenous American-like

ancestry.

Although our global ancestry analysis displayed minimal association between IA-like ancestry

and the risk of ALL, it is possible that this result was confounded by unascertained non-genetic

factors. Further, at known loci there is an enrichment of association between IA-like ancestry

and ALL risk, including strong associations at 7p12.2 and 10q21 that would have been genome-

wide significant in admixture mapping (**Table 2** above); this suggests that admixture mapping

may discover additional ALL risk loci. We thus performed admixture mapping using the CCRLP

and Kaiser/GERA Hispanic/Latino cohort as our discovery panel (1930 cases and 6417

controls). Our discovery admixture mapping analyses identified genome-wide significant

(threshold = 5.7×10^{-5} ; see **Methods**) signals at 2q21.2, 7p12.2, 10q21.2, and 15q22.31. The

loci on chromosomes 7 (*IKZF1*) and 10 (*ARID5B*) are known, while those on chromosomes 2

and 15 are potentially novel (**Figure 2**). Notably, when we restricted our analysis to a set of

Hispanic/Latino individuals inferred by HARE across all 10 cross-validation, which produced a

panel of 1729 cases and 4696 controls, we observed high correlation in odds ratios (Pearson's

correlation coefficient, r = 0. 913) and log *P*-values (r = 0.853), with a modest decrease in

significance of association among variants with *P*-values < 1e-3, including the four putative loci

(**Supplementary Table 13; Supplementary Figures 5-6**), likely reflecting the smaller sample

size.

470
Figure 2: Manhattan plot of the admixture mapping analysis. *The analysis identified signals*

at 2q21.2, 7p12.2, 10q21.2, and 15q22.31. The significance threshold is 5.7e-5.

We then fine-mapped each of the four loci identified by admixture mapping via single-variant

regional association testing (**Methods**), which uncovered the putative lead SNPs in each region

to be 2:133605881 (p = 4.21 e-5), 7:50395237 (p = 2.26 e-12), 10:61959980 (p = 2.25e-44),

and 15:66111790 (p = 3.01 e-4; **Table 3**). SNPs on chr2, 7, and 10 surpassed the regional

significance threshold after accounting the number of tests performed in each region via

permutation (**Methods**), and chr15 SNP was barely below the threshold. These SNPs exhibit

allele frequency differences by ancestry group (**Table 3**), and conditioning on these SNPs also

strongly attenuated the admixture mapping association (except for chr 15; **Table 3)**. We sought

replication of these associations in additional Hispanic/Latino cohorts, including cases from

CCLS, COG, and REDIAL (see **Methods**), totaling 1951 cases and 3,918 controls. In the meta-

analyzed replication cohorts, only the lead SNPs or other SNPs in LD with the lead SNPs on

chromosomes 7 and 10 were statistically significant (**Supplementary Table 14-15**).

Chr	Pos (Hg38)	rsID	Locus	Ref	Risk	$OR_{Top\ SNP}$ (95% CI)	$P_{Top\ SNP}$	RAF^*_{EUR}	RAF_{AFR}	RAF_{IA}	Gene	P_{crude}	P_{adj}	Peak Region
2	134116620	rs117345013	2q21.2	T	C	1.22 (1.11, 1.72)	4.209×10^{-5}	0.010	0.000	0.390	Unknown	4.156×10^{-6}	0.005	133605881, 134236147
7	50390453	rs6969942	7p12.2	C	T	1.35 (1.25, 1.47)	2.262×10^{-12}	0.507	0.773	0.870	IKZFI	7.315×10^{-8}	0.002	50352094, 50457722
10	61959980	rs4948492	10q21.2	T	C	1.85 (1.59, 2.13)	2.245×10^{-44}	0.295	0.162	0.441	ARID5B	3.210×10^{-5}	0.202	61928110, 62306779
15	65877726	rs12438510	15q22.31	G	A	1.23 (1.10,1.39)	3.011×10^{-4}	0.000	0.000	0.340	RAB11A	3.916×10^{-5}	6.718×10^{-5}	65540837, 66146213

510
511

***Table 3**: **Odds Ratios, 95% CI's, and p-values of top SNPs from regional association testing, under the admixture peak, as**

well as the crude and adjusted p-values of the admixture mapping tag SNP. The regional significance thresholds, determined via

permutation to account for the regional multiple testing burden, are 7.906x10^-5, 6.256x10^-4, xs1.905x10^-3, and 1.270x10^-4 for 2q21.2,

7p12.2, 10q21.2, and 15q22.31, respectively.*Risk allele frequencies (RAF) per ancestry group were obtained from European

(Orcadian, Russian, Tuscan, French, Basque, Bergamo, Sardinian, Adygei), African (Bantu, Mbuti, Biaka, San, Yoruba, Mandenka),

and Indigenous American (Surui, Karitiana, Maya, Pima, Colombian) superpopulation data from the Human Genome Diversity Project

(accessed from the Genome Aggregation Database[38] v4).*

Discussion:

Motivated by the increased risk of ALL in Hispanic/Latino children and the potential role of ancestry, we carried out a systematic investigation into the impact of IA-like ancestry on childhood ALL risk, both at the local and global level. Globally, we found no evidence that IA-like ancestry is statistically associated with ALL risk. The lack of global ancestry association, however, did not preclude an association at the local level, as IA-like ancestry was strongly associated with ALL risk across known loci and risk alleles segregated with the IA haplotype more often than expected. Together, these results suggest that, in addition to environmental factors, risk alleles present in higher frequencies in IA populations contribute to Hispanics/Latinos' excess risk of B-cell ALL. Further, this work seeks to inform best practices for performing analyses in admixed populations, including considerations for stratifying by self-reported or genetically inferred ancestry and estimating the effect of genetic ancestry on disease risk, in the presence of confounding by socio-cultural variables.

Within the genetic epidemiology literature, careful consideration has been given to the use of self-reported race/ethnicity or genetically inferred ancestry as strata in performing GWAS. For instance, it is common to define "White British" based on demographic data complemented by principal components of the genotype data when analyzing UK Biobank to remove concerns of stratification[59–61]. However, this notion of defining a homogenous subset of the population does not completely remove the effect of stratification even in a relatively homogenous cohort such as the UKB[62], and becomes even more difficult when performing analysis in multi-ancestry cohorts or admixed populations. In those cases, one can pool samples across all ancestries for a "mega-analysis"[63], or perform stratified analysis using either (1) self-reported demographic labels[19,33,64] or (2) some arbitrary heuristics based on genetically inferred ancestry[20,24,65,66]. The proposed downside of using genetically inferred ancestry is the prescription of arbitrary thresholds to define ancestry strata. Across studies, the inclusion criteria vary, with individuals of self-reported White,

Black and Asian race/ethnicity being defined as study participants with over 75-95% European-

like, 50-90% African-like, and 75-90% Asian-like ancestries, respectively[20,24,65–68] .

Previous genetic studies involving Hispanic/Latino participants have defined their strata as

individuals whose IA ancestry was greater or equal to 10% *and* greater than the proportion of

African ancestry[66,69,70]. Given the heterogeneity of Hispanics/Latinos as a population, this method

of categorization may prove untenable. The admixture proportions of Hispanic/Latino individuals

vary by country of origin with Caribbean and mainland Hispanics/Latinos exhibiting the highest

levels of African-like and IA-like ancestry, respectively[71,72]. Moreover, the estimated admixture

proportions can vary depending on the reference samples available, as well as the geographic

and temporal definitions of an ancestry component one wishes to estimate. Given these nuances,

we have tended to favor relying on self-reported demographic labels as strata when performing

multi-ancestry GWAS[33,73] or when limiting our analyses to Hispanics/Latinos[13]. Indeed, even if

overt categorizations impact little of the statistical power of the study design and may provide a

bit more robustness to the study, the underlying message conveyed by explicit categorization of

people based on estimated genetic ancestry may bring more harm than benefits.

In the present study, we evaluated the impact of our choice of relying on self-reported

demographic labels. When considering the multi-ancestry cohorts of CCRLP/Kaiser-GERA

together, the HARE analysis revealed low misclassification of individuals (0.18-3.37% across four

ethnic groups), suggesting that the algorithm rarely has enough evidence to suggest that a

person's self-reported label is inconsistent with their genetically inferred ancestry. The

discordance between HARE-imputed labels and the self-reported label is greater when we

masked the self-reported labels in a subset of the individuals. The most frequent discordance was

found among Hispanics/Latinos, reflecting their genetic heterogeneity across principal component

spaces. This is consistent with Hispanics/Latinos having the most complicated admixture profile

and history in our cohort, and with the notion that it is challenging to genetically define and clearly

delineate the Hispanic/Latino population based on genetics[63] . When we conducted our admixture

mapping study using this genetically inferred subset of individuals (N = 6425), we found highly

concordant results (r = 0.913 for effect sizes; **Supplementary Figures 5-6**). This analysis did not

identify additional signals; instead, the analysis was underpowered, with only the loci on

chromosomes 7 and 15 surpassing the genome-wide significance threshold. Given these results,

we elected to continue using self-reported demographic labels for inclusion of our studies

involving Hispanics/Latinos. We continue to use rigorous statistical approaches to control for

possibility of population stratification in association studies, as well as detailed characterization

and scrutiny of any potential findings.

Our in-depth investigation into inferred genetic ancestry also adds to and clarifies previous

findings. A previous study using CCLS data found a positive, statistically significant association

between global IA-like ancestry and ALL risk[27] . This result may have been affected by selection

bias, due to the lower participation of CCLS controls than cases in lower SES areas[74]. In our re-

analysis of the CCLS dataset, we indeed found that the association of ALL risk with global IA-like

ancestry was attenuated and no longer statistically significant (though trending in the positive

direction) after adjusting for income and education level. In the CCRLP, in which controls were

ascertained through statewide birth records[33] and thus should not be impacted by selection bias,

we found no significant association between genetic ancestry and ALL risk. Associations between

global ancestries and disease risks are often reported, but these associations can be confounded

by unaccounted environmental factors. In Hispanics/Latinos, African-like or IA-like ancestries

have been shown to be inversely correlated with education levels and overall socioeconomic

status [28,57,75,76] and accounting for these abolished the previously statistically significant

association between ancestry and type-2 diabetes risk[28]. In other studies of African Americans,

the associations between global ancestry and diseases, such as hypertension and lung cancer,

also dissolved upon inclusion of socio-economic status in the model[57,77]. Therefore, a more robust

approach to investigate the relationship between global ancestry and disease risk would be to

include non-genetic factors or employ a family-based design[58,78].

Local ancestry is unlikely to be correlated with environmental factors, allowing for robust

estimation of ancestry-disease associations. We found that averaged across all known ALL loci

the risk alleles segregated with the IA-like haplotype more often than expected by chance (**Table**

2, **Supplemental Table 10**). On the other hand, we found no interaction between IA-like ancestry

and the risk genotype at either the local or global levels (**Supplemental Tables 11-12**),

suggesting that there is little evidence the risk alleles exert different effects in different ancestry

context. Our admixture mapping identified associations on chromosomes 2, 7, 10, and 15, but

SNPs at the putatively novel loci on chromosomes 2 and 15 did not replicate in additional

Hispanic/Latino cohorts. The chromosome 2 locus (2q21.2) is a relative gene desert but overlaps

MGAT5, which has been reported to be involved in cancer metastasis and tumor suppression in

mice[79] (Granovsky et al., 2000). Further, transcriptional regulation of the gene is driven by the

Ras-Raf-Ets pathway, which is oncogenic[80–82]. On chromosome 15, the gene closest to the

putative risk SNP is *RAB11A*, a member of the RAS oncogene family, and has been previously

associated with risk of lung squamous cell carcinoma[83] and ovarian cancer[84] . Further, this region

contains multiple SNP associations with blood cell phenotypes[85,86] , of relevance for the etiology

of childhood ALL[21] . Adjusting for the lead SNP did not strongly attenuate the chromosome 15

association identified by admixture mapping, suggesting that more complex genomic variation

such as structural variants, which may be in low LD with imputed SNPs[87], could underlie this

association and would require further validation. While there may be biological plausibility for

these potentially novel loci, the lack of replication could also be due to lack of statistical power,

heterogeneity of Hispanic/Latino populations across the United States, or that our initial findings

were statistical artefacts.

Finally, the results of our study have implications on future investigations of the genetic

architecture of ALL. As reflected in our findings, the elevated ALL risk in Hispanic/Latino children

is to some extent driven by the higher frequencies of known ALL risk alleles on IA-like haplotypes,

which may underlie the shift towards higher mean polygenic risk scores for ALL in

Hispanics/Latinos than in non-Latino Whites[73,88]. Moreover, in line with risk alleles being found

consistently enriched on IA-like haplotypes, IA-like ancestry at known loci is also more likely to be

associated with increasing risk. These consistent directional associations with risk could be

indicative of a signature of past adaptation. There is some evidence that ALL risk loci, such as

the *IKZF1* locus that we found to be genome-wide significant in admixture mapping, may be under

positive selection in Hispanic/Latino populations[13]. Given the overall enrichment of risk alleles on

IA haplotypes, the selection may be more polygenic. Careful scrutiny is needed to rule out other

potential confounding[59,89] though polygenic adaptation has been demonstrated in other traits[90,91].

Understanding this architecture, as well as continued discovery of ALL risk alleles that may

segregate with the Indigenous American haplotype or particular ancestries broadly, can aid in

precision medicine efforts and improve diagnostics, cancer screening, risk assessment, and

awareness, with the ultimate end of reducing disparities[92].

Acknowledgements

We would like to thank the families and patients who participated in each study for ALL, and Soyoung Jeon for helpful conversations contributing to this research. Data used in this study were generated with supports from multiple grants from the National Institutes of Health (R01CA155461, R01CA175737, R01ES009137, P42ES004705, P50ES018172, P42ES0470518, R24ES028524, P20CA262733, U24ES028524, and R01CA262263), the Environmental Protection Agency (RD83615901), the Cancer Prevention and Research Institute of Texas (RP160771, RP210064), and St. Baldrick's Foundation (consortium grant 522277 with support from the Micaela's Army Foundation). Analysis performed in this study was supported by F31CA278359 to J.L., R01CA262263 to A.J.D., and R35GM142783 to C.W.K.C. A.J.D. is a Scholar of the Leukemia & Lymphoma Society. The content and conclusions from this work do not reflect the official views of the sponsors. The collection of cancer incidence data used in this study was supported by the California Department of Public Health pursuant to California Health and Safety Code Section 103885; Centers for Disease Control and Prevention's (CDC) National Program of Cancer Registries, under cooperative agreement 1NU58DP007156; the National Cancer Institute's Surveillance, Epidemiology and End Results Program under contract HHSN261201800032I awarded to the University of California, San Francisco, contract HHSN261201800015I awarded to the University of Southern California, and contract HHSN261201800009I awarded to the Public Health Institute. The ideas and opinions expressed herein are those of the authors and do not reflect the opinions of the State of California, Department of Public Health, the National Cancer Institute, and the Centers for Disease Control and Prevention or their Contractors and Subcontractors. The biospecimens and/or data used in this study were obtained from the California Biobank Program (CBP request #26 and #1380) Section 6555(b), 17 CCR). The California Department of Public Health is not responsible for the results or conclusions drawn by the authors of this publication. Computation of this work is supported by USC's Center for Advanced Research Computing (https://www.carc.usc.edu/).

Data Availability Statement

Genetic data from CCRLP and CCLS were obtained from the California Biobank. Because samples and data are property of the State of California, researchers who would like to request to use the data should establish a protocol with the California Department of Public Health Committee for the Protection of Human Subjects and other relevant agencies to understand if approval to share data are acceptable. The State has provided the following guidance on data sharing, as noted in the following statement: "California has determined that researchers requesting the use of California Biobank biospecimens for their studies will need to seek an exemption from NIH or other granting or funder requirements regarding the uploading of study results into an external bank or repository (including into the NIH dbGaP or other bank or repository). This applies to any uploading of genomic data and/or sharing of these biospecimens or individual data derived from these biospecimens. Such activities have been determined to violate the statutory scheme at California Health and Safety Code Section 124980 (j), 124991 (b), (g), (h) and 103850 (a) and (d), which protect the confidential nature of biospecimens and individual data derived from biospecimens. Investigators may agree to share aggregate data on SNP frequency and their associated p values with other investigators and may upload such frequencies into repositories including the NIH dbGaP repository providing: a) the denominator from which the data is derived includes no fewer than 20,000 individuals; b) no cell count is for <5 individuals; and c) no correlations or linkage probabilities between SNPs are provided." Our data, from CCRLP and CCLS, are each comprised of less than 20,000 subjects and therefore cannot be uploaded to a repository such as dbGaP. Data from Children's Oncology Group and REDIAL were obtained by special request (Yang et al., 2011; Harris et al., 2023). Data from MESA (phs000209.v13.p3) and HCHS/SOL (phs000810.v2.p2.c1, phs000810.v2.p2.c2) were obtained from dbGaP.

699
700 **References**
701
1. Bhojwani, D., Yang, J. J. & Pui, C.-H. Biology of Childhood Acute Lymphoblastic Leukemia.

Pediatr. Clin. North Am. **62**, 47–60 (2015).

2. Rheingold, S. R. *et al.* Determinants of survival after first relapse of acute lymphoblastic

leukemia: a Children's Oncology Group study. *Leukemia* **38**, 2382–2394 (2024).

3. Einsiedel, H. G. *et al.* Long-term outcome in children with relapsed ALL by risk-stratified

salvage therapy: results of trial acute lymphoblastic leukemia-relapse study of the Berlin-

Frankfurt-Münster Group 87. *J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol.* **23**, 7942–7950

(2005).

4. Nguyen, K. *et al.* Factors Influencing Survival After Relapse From Acute Lymphoblastic

Leukemia: A Children's Oncology Group Study. *Leuk. Off. J. Leuk. Soc. Am. Leuk. Res. Fund*

UK **22**, 2142–2150 (2008).

5. Hunger, S. P. & Raetz, E. A. How I treat relapsed acute lymphoblastic leukemia in the

pediatric population. *Blood* **136**, 1803–1812 (2020).

6. Devilli, L. *et al.* Long-term and quality of survival in patients treated for acute lymphoblastic

leukemia during the pediatric age. *Hematol. Rep.* **13**, 8847 (2021).

7. Pui, C.-H., Robison, L. L. & Look, A. T. Acute lymphoblastic leukaemia. *The Lancet* **371**,

1030–1043 (2008).

8. Sasaki, K. *et al.* Acute lymphoblastic leukemia: A population-based study of outcome in the

United States based on the surveillance, epidemiology, and end results (SEER) database,

1980–2017. *Am. J. Hematol.* **96**, 650–658 (2021).

9. American Cancer Society. Key Statistics for Acute Lymphocytic Leukemia (ALL). *American*

Cancer Society https://www.cancer.org/cancer/types/acute-lymphocytic-leukemia/about/key-

statistics.html (2024).

10.   Feng, Q. *et al.* Trends in Acute Lymphoblastic Leukemia Incidence in the United States

by Race/Ethnicity From 2000 to 2016. *Am. J. Epidemiol.* **190**, 519–527 (2021).

11.   Quiroz, E. *et al.* Immunophenotype of acute lymphoblastic leukemia in minorities-

analysis from the SEER database. *Hematol. Oncol.* **40**, 105–110 (2022).

12.   de Smith, A. J., Jiménez-Morales, S. & Mejía-Aranguré, J. M. The genetic risk of acute

lymphoblastic leukemia and its implications for children of Latin American origin. *Front.*

Oncol. **13**, 1299355 (2024).

13.   de Smith, A. J. *et al.* A noncoding regulatory variant in IKZF1 increases acute

lymphoblastic leukemia risk in Hispanic/Latino children. *Cell Genomics* **4**, (2024).

14.   Thomas, D. C. *Statistical Methods in Genetic Epidemiology*. (Oxford University Press,

Oxford ; New York, 2004).

15.   Swords, R. *et al.* Acute leukemia in adult Hispanic Americans: a large-population study.

Blood Cancer J. **6**, e484 (2016).

16.   Pollyea, D. A. *et al.* Acute Leukemia in Hispanic Americans: Incidence and Incidence

Rate Differences by Nativity. *Blood* **120**, 3160 (2012).

17.   Dong, Y. *et al.* Leukemia incidence trends at the global, regional, and national level

between 1990 and 2017. *Exp. Hematol. Oncol.* **9**, 14 (2020).

18.   Yi, M., Zhou, L., Li, A., Luo, S. & Wu, K. Global burden and trend of acute lymphoblastic

leukemia from 1990 to 2017. *Aging* **12**, 22869–22891 (2020).

19.   Jeon, S., Smith, A. J. & Li, S. Genome-wide trans-ethnic meta-analysis identifies novel

susceptibility loci for childhood acute lymphoblastic leukemia. *Leukemia* **36**, 865–868 (2022).

20.   Vijayakrishnan, J. *et al.* Identification of four novel associations for B-cell acute

lymphoblastic leukaemia risk. *Nat. Commun.* **10**, 5348 (2019).

21.   Kachuri, L. *et al.* Genetic determinants of blood-cell traits influence susceptibility to

childhood acute lymphoblastic leukemia. *Am. J. Hum. Genet.* **108**, 1823–1835 (2021).

22.   Qian, M. *et al.* Novel susceptibility variants at the ERG locus for childhood acute

lymphoblastic leukemia in Hispanics. *Blood* **133**, 724–729 (2019).

23.   Xu, H. *et al.* ARID5B genetic polymorphisms contribute to racial disparities in the

incidence and treatment outcome of childhood acute lymphoblastic leukemia. *J. Clin. Oncol.*

Off. J. Am. Soc. Clin. Oncol. **30**, 751–757 (2012).

24.   Perez-Andreu, V. *et al.* Inherited GATA3 variants are associated with Ph-like childhood

acute lymphoblastic leukemia and risk of relapse. *Nat. Genet.* **45**, 1494–1498 (2013).

25.   Bryc, K., Durand, E. Y., Macpherson, J. M., Reich, D. & Mountain, J. L. The genetic

ancestry of african americans, latinos, and european Americans across the United States.

Am. J. Hum. Genet. **96**, 37–53 (2015).

26.   Homburger, J. R. *et al.* Genomic Insights into the Ancestry and Demographic History of

South America. *PLOS Genet.* **11**, e1005602 (2015).

27.   Walsh, K. *et al.* Associations between genome-wide Native American ancestry, known

risk alleles and B-cell ALL risk in Hispanic children. *Leukemia* **27**, 10.1038/leu.2013.130

(2013).

28.   Florez, J. C. *et al.* Strong association of socioeconomic status with genetic ancestry in

Latinos: implications for admixture studies of type 2 diabetes. *Diabetologia* **52**, 1528–1536

(2009).

29.   Thornton, T. A. & Bermejo, J. L. Local and Global Ancestry Inference, and Applications

to Genetic Association Analysis for Admixed Populations. *Genet. Epidemiol.* **38**, S5–S12

(2014).

30.   de Smith, A. J. *et al.* Heritable variation at the chromosome 21 gene ERG is associated

with acute lymphoblastic leukemia risk in children with and without Down syndrome.

Leukemia **33**, 2746–2751 (2019).

31.   Committee on the Use of Race, Ethnicity, and Ancestry as Population Descriptors in

Genomics Research *et al. Using Population Descriptors in Genetics and Genomics*

Research: A New Framework for an Evolving Field. 26902 (National Academies Press,

Washington, D.C., 2023). doi:10.17226/26902.

32. Zavala, V. A. *et al.* Cancer health disparities in racial/ethnic minorities in the United

States. *Br. J. Cancer* **124**, 315–332 (2021).

33. Wiemels, J. L. *et al.* GWAS in childhood acute lymphoblastic leukemia reveals novel

genetic associations at chromosomes 17q12 and 8q24.21. *Nat. Commun.* **9**, 286 (2018).

34. Ma, X., Buffler, P. A., Layefsky, M., Does, M. B. & Reynolds, P. Control Selection

Strategies in Case-Control Studies of Childhood Diseases. *Am. J. Epidemiol.* **159**, 915–921

(2004).

35. Harris, R. D. *et al.* Ethnic-Specific Predictors of Neurotoxicity Among Pediatric Acute

Lymphoblastic Leukemia Patients Following High-Dose Methotrexate. *Cancer* **129**, 1287–

1294 (2023).

36. Sheng, X. *et al.* Inverted genomic regions between reference genome builds in humans

impact imputation accuracy and decrease the power of association testing. *Hum. Genet.*

Genomics Adv. **4**, (2023).

37. Maples, B. K., Gravel, S., Kenny, E. E. & Bustamante, C. D. RFMix: a discriminative

modeling approach for rapid and robust local-ancestry inference. *Am. J. Hum. Genet.* **93**,

278–288 (2013).

38. Karczewski, K. J. *et al.* The mutational constraint spectrum quantified from variation in

141,456 humans. *Nature* **581**, 434–443 (2020).

39. Li, S. *et al.* Localized variation in ancestral admixture identifies pilocytic astrocytoma risk

loci among Latino children. *PLoS Genet.* **18**, e1010388 (2022).

40. Kowalski, M. H. *et al.* Use of 100,000 NHLBI Trans-Omics for Precision Medicine

(TOPMed) Consortium whole genome sequences improves imputation quality and detection

of rare variant associations in admixed African and Hispanic/Latino populations. *PLoS Genet.*

15, 1008500 (2019).

41.   Cahoon, J. L. *et al.* Imputation accuracy across global human populations. *Am. J. Hum.*

Genet. **111**, 979–989 (2024).

42.   Fang, H. *et al.* Harmonizing Genetic Ancestry and Self-identified Race/Ethnicity in

Genome-wide Association Studies. *Am. J. Hum. Genet.* **105**, 763–772 (2019).

43.   Chang, C. C. *et al.* Second-generation PLINK: rising to the challenge of larger and richer

datasets. *GigaScience* **4**, 7 (2015).

44.   Metayer, C. *et al.* Tobacco Smoke Exposure and the Risk of Childhood Acute

Lymphoblastic and Myeloid Leukemias by Cytogenetic Subtype. *Cancer Epidemiol.*

Biomarkers Prev. **22**, 1600–1611 (2013).

45.   R Core Team. R: A Language and Environment for Statistical Computing. R Foundation

for Statistical Computing (2023).

46.   Purcell, S. *et al.* PLINK: A Tool Set for Whole-Genome Association and Population-

Based Linkage Analyses. *Am. J. Hum. Genet.* **81**, 559–575 (2007).

47.   Qian, M. *et al.* Genome-Wide Association Study of Susceptibility Loci for T-Cell Acute

Lymphoblastic Leukemia in Children. *J. Natl. Cancer Inst.* **111**, 1350–1357 (2019).

48.   Brown, L. A. *et al.* Admixture Mapping Identifies an Amerindian Ancestry Locus

Associated with Albuminuria in Hispanics in the United States. *J. Am. Soc. Nephrol. JASN*

28, 2211–2220 (2017).

49.   Schick, U. M. *et al.* Genome-wide Association Study of Platelet Count Identifies

Ancestry-Specific Loci in Hispanic/Latino Americans. *Am. J. Hum. Genet.* **98**, 229–242

(2016).

50.   Qin, H. & Zhu, X. Power Comparison of Admixture Mapping and Direct Association

Analysis in Genome-Wide Association Studies. *Genet. Epidemiol.* **36**, 235–243 (2012).

51.   Willer, C. J., Li, Y. & Abecasis, G. R. METAL: fast and efficient meta-analysis of

genomewide association scans. *Bioinformatics* **26**, 2190–2191 (2010).

52.   Peterson, R. E. *et al.* Genome-wide association studies in ancestrally diverse

populations: opportunities, methods, pitfalls, and recommendations. *Cell* **179**, 589–603

(2019).

53.   Reich, D. *et al.* Reconstructing Native American population history. *Nature* **488**, 370–374

(2012).

54.   Iyer, H. S., Gomez, S. L., Cheng, I. & Rebbeck, T. R. Relative impact of genetic ancestry

and neighborhood socioeconomic status on all-cause mortality in self-identified African

Americans. *PLOS ONE* **17**, e0273735 (2022).

55.   Institute of Medicine (US) Committee on Understanding and Eliminating Racial and

Ethnic Disparities in Health Care. *Unequal Treatment: Confronting Racial and Ethnic*

Disparities in Health Care. (National Academies Press (US), Washington (DC), 2003).

56.   Burchard, E. G. *et al.* The Importance of Race and Ethnic Background in Biomedical

Research and Clinical Practice. *N. Engl. J. Med.* **348**, 1170–1175 (2003).

57.   Aldrich, M. C. *et al.* Socioeconomic Status and Lung Cancer: Unraveling the Contribution

of Genetic Admixture. *Am. J. Public Health* **103**, e73–e80 (2013).

58.   Sun, H. *et al.* The impact of global and local Polynesian genetic ancestry on complex

traits in Native Hawaiians. *PLOS Genet.* **17**, e1009273 (2021).

59.   Sohail, M. *et al.* Polygenic adaptation on height is overestimated due to uncorrected

stratification in genome-wide association studies. *eLife* **8**, e39702 (2019).

60.   Bycroft, C. *et al.* The UK Biobank resource with deep phenotyping and genomic data.

Nature **562**, 203–209 (2018).

61.   Astle, W. J. *et al.* The Allelic Landscape of Human Blood Cell Trait Variation and Links to

Common Complex Disease. *Cell* **167**, 1415-1429.e19 (2016).

62.   Chen, M. *et al.* Evidence of Polygenic Adaptation in Sardinia at Height-Associated Loci

Ascertained from the Biobank Japan. *Am. J. Hum. Genet.* **107**, 60–71 (2020).

63.   Wojcik, G. L. *et al.* Genetic analyses of diverse populations improves discovery for

853   complex traits. *Nature* **570**, 514–518 (2019).

854   64.   Kachuri, L. *et al.* Genetically adjusted PSA levels for prostate cancer screening. *Nat.*

855   *Med.* **29**, 1412–1423 (2023).

856   65.   Klarin, D. *et al.* Genetics of blood lipids among ~300,000 multi-ethnic participants of the

857   Million Veteran Program. *Nat. Genet.* **50**, 1514–1523 (2018).

858   66.   Xu, H. *et al.* Novel susceptibility variants at 10p12.31-12.2 for childhood acute

859   lymphoblastic leukemia in ethnically diverse populations. *J. Natl. Cancer Inst.* **105**, 733–742

860   (2013).

861   67.   Gautam, Y. *et al.* Genome-wide admixture and association analysis identifies African

862   ancestry specific risk loci of eosinophilic esophagitis in African American. *J. Allergy Clin.*

863   *Immunol.* **151**, 1337–1350 (2023).

864   68.   Shrine, N. *et al.* Multi-ancestry genome-wide association analyses improve resolution of

865   genes and pathways influencing lung function and chronic obstructive pulmonary disease

866   risk. *Nat. Genet.* **55**, 410–422 (2023).

867   69.   Archer, N. P. *et al.* Family-based exome-wide association study of childhood acute

868   lymphoblastic leukemia among Hispanics confirms role of ARID5B in susceptibility. *PLOS*

869   *ONE* **12**, e0180488 (2017).

870   70.   Karol, S. E. *et al.* Genetics of ancestry-specific risk for relapse in acute lymphoblastic

871   leukemia. *Leukemia* **31**, 1325–1332 (2017).

872   71.   Conomos, M. P. *et al.* Genetic diversity and association studies in US Hispanic/Latino

873   populations: applications in the Hispanic Community Health Study/Study of Latinos. *Am. J.*

874   *Hum. Genet.* **98**, 165–184 (2016).

875   72.   Bryc, K. *et al.* Genome-wide patterns of population structure and admixture among

876   Hispanic/Latino populations. *Proc. Natl. Acad. Sci.* **107**, 8954–8961 (2010).

73.   Jeon, S. *et al.* Genome-wide trans-ethnic meta-analysis identifies novel susceptibility loci

for childhood acute lymphoblastic leukemia. *Leukemia* **36**, 865–868 (2022).

74.   Wheeler, D. C., Boyle, J., Carli, M., Ward, M. H. & Metayer, C. Neighborhood

Deprivation, Indoor Chemical Concentrations, and Spatial Risk for Childhood Leukemia. *Int.*

J. Environ. Res. Public. Health **20**, 3582 (2023).

75.   Zou, J. Y. *et al.* Genetic and socioeconomic study of mate choice in Latinos reveals

novel assortment patterns. *Proc. Natl. Acad. Sci.* **112**, 13621–13626 (2015).

76.   da Silva, T. M. *et al.* Biogeographical ancestry is associated with socioenvironmental

conditions and infections in a Latin American urban population. *SSM - Popul. Health* **4**, 301–

306 (2018).

77.   Non, A. L., Gravlee, C. C. & Mulligan, C. J. Education, Genetic Ancestry, and Blood

Pressure in African Americans and Whites. *Am. J. Public Health* **102**, 1559–1565 (2012).

78.   Asgari, S. *et al.* A positively selected FBN1 missense variant reduces height in

Peruvians. *Nature* **582**, 234–239 (2020).

79.   Granovsky, M. *et al.* Suppression of tumor growth and metastasis in Mgat5-deficient

mice. *Nat. Med.* **6**, 306–312 (2000).

80.   Hirata, A. *et al.* Increased risk of metastasis in patients with incidental use of renin-

angiotensin system inhibitors: a retrospective analysis for multiple types of cancer based on

electronic medical records. *Hypertens. Res.* **45**, 1869–1881 (2022).

81.   Kang, R. *et al.* Transcriptional Regulation of the N-Acetylglucosaminyltransferase V

Gene in Human Bile Duct Carcinoma Cells (HuCC-T1) Is Mediated by Ets-1 *. *J. Biol. Chem.*

271, 26706–26712 (1996).

82.   Buckhaults, P., Chen, L., Fregien, N. & Pierce, M. Transcriptional Regulation ofN-

Acetylglucosaminyltransferase V by the srcOncogene *. *J. Biol. Chem.* **272**, 19575–19581

(1997).

83.   Gombodorj, N. *et al.* RAB11A Expression Is Associated With Cancer Aggressiveness

Through Regulation of FGFR-Signaling in Lung Squamous Cell Carcinoma. *Ann. Surg.*

Oncol. **29**, 7149–7162 (2022).

84.   Wang, Y., Ren, Y., Li, N., Zhao, J. & Zhao, S. Rab11a promotes the malignant

progression of ovarian cancer by inducing autophagy. *Genes Genomics* **44**, 1375–1384

(2022).

85.   Vuckovic, D. *et al.* The Polygenic and Monogenic Basis of Blood Traits and Diseases.

Cell **182**, 1214-1231.e11 (2020).

86.   Chen, M.-H. *et al.* Trans-ethnic and ancestry-specific blood-cell genetics in 746,667

individuals from 5 global populations. *Cell* **182**, 1198-1213.e14 (2020).

87.   Sudmant, P. H. *et al.* An integrated map of structural variation in 2,504 human genomes.

Nature **526**, 75–81 (2015).

88.   Jeon, S. *et al.* Evaluating Genomic Polygenic Risk Scores for Childhood Acute

Lymphoblastic Leukemia in Latinos. *MedRxiv Prepr. Serv. Health Sci.* 2023.06.08.23291167

(2023) doi:10.1101/2023.06.08.23291167.

89.   Berg, J. J. *et al.* Reduced signal for polygenic adaptation of height in UK Biobank. *eLife*

8, e39725 (2019).

90.   Le, M. K. *et al.* 1,000 ancient genomes uncover 10,000 years of natural selection in

Europe. 2022.08.24.505188 Preprint at https://doi.org/10.1101/2022.08.24.505188 (2022).

91.   Chen, M. *et al.* Evidence of Polygenic Adaptation in Sardinia at Height-Associated Loci

Ascertained from the Biobank Japan. *Am. J. Hum. Genet.* **107**, 60–71 (2020).

92.   Jorde, L. B. & Bamshad, M. J. Genetic Ancestry Testing What Is It and Why Is It

Important? *JAMA* **323**, 1089–1090 (2020).

925